GlassScriptPhysician profile
Rosa V Rances
NPI 1902311038
$16,889.43
in general payments reported to CMS, 2019-2025
45 companies · $2,258 in 2025
The $2,258 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,276 · 2022: $1,262 · 2023: $4,337 · 2024: $5,757 · 2025: $2,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,950 · Travel and Lodging: $2,163 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,950.44 |
| Travel and Lodging | $2,162.85 |
| Education | $238.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $2,171.47 | 2024-2025 | Evoke |
| Relievant Medsystems, INC. | $1,889.04 | 2021-2023 | Intracept |
| Abbvie INC. | $1,877.35 | 2021-2025 | |
| Boston Scientific Corporation | $1,674.23 | 2021-2025 | Intracept, Wavewriter Alpha Prime 16, General - Pain Management |
| Biohaven Pharmaceuticals, INC. | $1,469.92 | 2021 | |
| Tersera Therapeutics LLC | $1,434.03 | 2021-2025 | Prialt |
| Merz Pharmaceuticals, LLC | $854.69 | 2021-2025 | Xeomin |
| Mml US, INC. | $672.01 | 2023-2025 | Reactiv8 |
| Medtronic, INC. | $620.50 | 2023-2025 | Synchromedii, Intellis Adaptivestim, V-Loc 180 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $518.55 | 2021-2025 | Relistor |
| Pfizer INC. | $433.56 | 2023-2025 | |
| Painteq LLC | $416.00 | 2022-2024 | Painteq |
| Collegium Pharmaceutical, INC. | $399.50 | 2021-2025 | Xtampza, Belbuca, Nucynta |
| Nalu Medical, INC. | $314.34 | 2024 | Nalu Neurostimulation System |
| Spinal Simplicity, LLC | $204.17 | 2023 | Ha Minuteman G3-R |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $177.08 | 2023-2025 | Qutenza |
| Eisai INC. | $144.04 | 2021 | |
| Horizon Therapeutics Plc | $139.96 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $129.15 | 2025 | |
| Abbott Laboratories | $116.41 | 2024 | Proclaim |
| Ibsa Pharma INC. | $93.54 | 2021-2023 | Tirosint, Licart |
| Amgen INC. | $91.27 | 2021 | |
| Pacira Therapeutics, INC. | $81.63 | 2021 | |
| Biodelivery Sciences International, INC. | $80.95 | 2021 | |
| Glaxosmithkline, LLC. | $70.10 | 2023 | Shingrix |
| Piramal Critical Care | $67.13 | 2024-2025 | |
| Axsome Therapeutics, INC. | $65.05 | 2025 | Symbravo |
| Ipsen Biopharmaceuticals, INC | $62.71 | 2025 | Dysport |
| Masimo Corporation | $62.41 | 2023-2024 | Patient Safetynet System |
| Arbor Pharmaceuticals, INC. | $62.09 | 2021 | |
| Azurity Pharmaceuticals, INC. | $58.50 | 2023 | Horizant |
| Lilly USA, LLC | $58.47 | 2021-2025 | Reyvow, Emgality, Zepbound |
| Spr Therapeutics, INC | $56.87 | 2025 | Sprint Pns System |
| Valinor Pharma, LLC | $48.73 | 2025 | Movantik |
| Novartis Pharmaceuticals Corporation | $40.15 | 2021 | |
| Hikma Pharmaceuticals USA | $36.79 | 2023-2024 | Kloxxado |
| Scilex Pharmaceuticals INC. | $34.96 | 2021-2023 | Ztlido |
| Si-Bone, INC. | $31.70 | 2021-2025 | |
| Innovation Technologies INC | $25.78 | 2024 | Irrisept |
| Curonix LLC | $25.32 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Radius Health, INC. | $17.18 | 2021 | |
| Almatica Pharma LLC | $16.09 | 2021 | |
| Virtus Pharmaceuticals LLC | $15.71 | 2021 | |
| Allergan, INC. | $15.57 | 2021 | |
| Redhill Biopharma INC. | $14.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa Rances listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.